Demand-release bioactive composition for implantable medical devices

• US 8,673,339 B2
• Filed: 03/11/2003
• Issued: 03/18/2014
• Est. Priority Date: 03/11/2003
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Stokes, Kenneth B., Ebert, Michael J., Hobot, Christopher M.
• Primary Examiner(s): Kwon, Brian-Yong
• Assistant Examiner(s): BECKHARDT, LYNDSEY MARIE
• Application Number:
  US10/386,967
• Publication Number:
  US 20040180073A1
• Time in Patent Office: 4,025 Days
• Field of Search: None
• US Class Current: 424/426
• CPC Class Codes: A61L 2300/222 Steroids, e.g. corticosteroids
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61N 1/056 Transvascular endocardial electrode systems
• CPC Class Codes: A61N 1/0575 with drug delivery
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A biostable polymeric substrate of an implantable medical device unit includes a demand-release bioactive composition including one or more bioactive agents covalently bound to surface-modifying end groups of the substrate. Certain cellular activities, in proximity to the polymeric substrate, release substances reacting with the end groups such that the end groups release the one or more bioactive agents, which modify the certain cellular activities.

Claims

1. A medical device comprising:

an implantable unit comprising a bulk polymeric material including surface-modifying end groups provided throughout the bulk of the polymeric material; and

a demand-release bioactive composition provided within and throughout the bulk of the polymeric material included in the implantable unit, wherein the demand-release bioactive composition includes one or more bioactive agents covalently bound to the surface-modifying end groups, wherein the one or more bioactive agents are released when the surface-modifying end groups undergo one of oxidation, acid-catalyzed hydrolysis, or enzyme-catalyzed hydrolysis;

wherein certain cellular activities, in proximity to the polymeric substrate, release substances reacting with the surface-modifying end groups such that the surface-modifying end groups release the one or more bioactive agents, which modify the certain cellular activities;

wherein the cellular activities are initiated by macrophage activation; and

wherein the one or more bioactive agents are only released when the surface-modifying end groups undergo oxidation, acid-catalyzed hydrolysis, or enzyme-catalyzed hydrolysis following macrophage activation,

wherein the surface-modifying end groups are hydrolytically stable and oxidizable,

wherein the surface modifying end group comprises polymethylene oxide, and

wherein the one or more bioactive agents are bound to the polymethylene oxide.

2. The medical device of claim 1, wherein the implantable unit includes an intra-vascular portion.

3. The medical device of claim 1

wherein the polymeric material is a biostable polymeric material;

and

wherein the one or more bioactive agents comprises one or more bioactive anti-inflammatory agents.

4. The medical device of claim 3, wherein the implantable unit includes an intra-vascular portion.

5. The medical device of claim 1, wherein the one or more bioactive agents comprises an enzyme.

6. The medical device of claim 1, wherein the one or more bioactive agents comprises collagenase.

7. The medical device of claim 1, wherein the one or more bioactive agents comprises an anti-inflammatory agent.

8. The medical device of claim 3, wherein elevation of acute and chronic stimulation thresholds is avoided without the use of a monolithic controlled release device.

9. The medical device of claim 1, wherein elevation of acute and chronic stimulation thresholds is avoided without the use of a monolithic controlled release device.

10. The medical device of claim 1, wherein upon consumption of surface-modifying end groups at the surface of the polymeric material, additional surface-modifying end groups migrate from the bulk of the polymeric material to the surface of the polymeric material.

11. A medical device comprising:

an implantable unit;

a biostable polymeric substrate at least partially covering the unit and including surface-modifying end groups; and

a demand-release bioactive composition comprising one or more bioactive agents covalently bound to the surface-modifying end groups;

wherein the surface-modifying end groups are hydrolytically stable and oxidizable, such that cellular activities that occur in proximity to the polymeric substrate release substances that react with the surface-modifying end groups causing the surface-modifying end groups to release the one or more bioactive agents, which modify the certain cellular activities upon their release;

wherein the cellular activities are initiated by macrophage activation; and

wherein the surface modifying end groups are configured to release the one or more bioactive agents when the surface-modifying end groups undergo oxidation following macrophage activation,

wherein the surface modifying end groups comprise polymethylene oxide, and

wherein the one or more bioactive agents are bound to the polymethylene oxide.

12. The medical device of claim 11, wherein the one or more bioactive agents comprises an anti-inflammatory agent.